Eli Lilly (LLY) has been actively progressing its pharmaceutical offerings and forging new alliances, as recent product ...

Novo Nordisk faces slowing demand, rising competition, and CEO transition. Learn about challenges impacting its growth and ...

CEO-to-be Maziar Mike Doustdar will need to stem the company’s tumbling share price as market pressures intensify.

ASX companies such as LTR Pharma are finding smarter ways to stretch the value of existing assets and launch into broader ...

Eli Lilly's stock took a noticeable dip following a guidance update from rival Novo Nordisk. Investors reacted sharply as ...

Novo Nordisk's market value plummeted by $70 billion following a profit warning and the appointment of Maziar Mike Doustdar as the new CEO. The company slashed its 2025 sales growth outlook due to ...

Danish drugmaker Novo Nordisk's stock was down nearly 20% in premarket trading Tuesday morning after the company cut its ...

Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...

Novo, which became Europe’s most valuable listed company following the launch of Wegovy in 2021, is now facing a reckoning as ...

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 4.3% in the morning session after its key competitor in the ...

Novo Nordisk stocks plunged by 7% in premarket trading following an announcement by the company that it has lowered its ...

Novo Nordisk stock crashed over 20% in premarket trading after the company cut its 2025 forecast for the second time.